Morepen Labs Eyes Rs 5,000 Cr Revenue by FY30 – Can India’s API Push Fuel the Growth?

Morepen Laboratories has set an ambitious target of ₹5,000 crore in revenue by FY30, signaling a strong growth vision in the Active Pharmaceutical Ingredient (API) and diagnostics segments. This aligns with India’s broader objective of becoming self-reliant in pharma manufacturing through the PLI (Production-Linked Incentive) scheme and API parks. The global push for supply chain diversification post-COVID, coupled with India's cost competitiveness, is creating fertile ground for Indian mid-cap pharma companies to scale. Morepen's focus on expanding its API portfolio, investing in capacity building, and leveraging global regulatory approvals could act as key levers for growth. From a market standpoint, this puts Morepen in a favorable spot alongside players like

, , and , all of which are strategically expanding their API footprints. While long-term prospects appear robust, execution and regulatory compliance will remain crucial. Investors tracking the API space may want to keep an eye on margin trends, capacity utilization, and international order flows. Source: NDTV Profit No Recommendations